Author:
Ezaki Taisuke,Matsumoto Kazuhiro,Morita Shinya,Shinoda Kazunobu,Mizuno Ryuichi,Kikuchi Eiji,Oya Mototsugu
Reference16 articles.
1. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium;Sternberg;J Urol,1988
2. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000
3. Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
4. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03);Bamias;Ann Oncol,2013
5. Administration of gemcitabine and cisplatin in cancer patients with renal failure under hemodialysis;Chang;J BUON,2013
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献